연구성과로 돌아가기
2023 연구성과 (146 / 285)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study | Background/Aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL). Methods: Patients with newly diagnosed ALL, aged >= 15 years, were eligible for the study if their leukemic blast cells in bone marrow expressed CD20 >= 20% at the time of diagnosis. Patients received multiagent chemotherapy with rituximab. After achieving complete remission (CR), patients received five cycles of consolidation with concomitant rituximab. Rituximab was administered monthly from day 90 of transplantation for patients who received allogeneic hematopoietic cell transplantation. Results: In patients with Philadelphia (Ph)-negative ALL, 39 of 41 achieved CR (95.1%), the 2- and 4-year relapse-free survival (RFS) rates were 50.4% and 35.7%, and the 2- and 4-year overall survival (OS) rates were 51.5% and 43.2%, respectively. In the group with Ph-positive ALL, all 32 patients achieved CR, the 2- and 4-year RFS rates were 60.7% and 52.1%, and the 2- and 4-year OS rates were 73.3% and 52.3%, respectively. In the Ph-negative ALL group, patients with higher CD20 positivity experienced more favorable RFS (p < 0.001) and OS (p = 0.06) than those with lower CD20 positivity. Patients who received = 2 cycles of rituximab after transplantation had significantly improved RFS (hazard ratio [HR], 0.31; p = 0.049) and OS (HR, 0.29; p = 0.021) compared with those who received < 2 cycles. Conclusions: The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials.gov NCT01429610). | Baek, Dong Won; Park, Han-Seung; Sohn, Sang Kyun; Kim, Dae Young; Kim, Inho; Ahn, Jae-Sook; Do, Young Rok; Lee, Se Ryeon; Eom, Hyeon-Seok; Lee, Won-Sik; Kim, Sung-Hyun; Lee, Ho Sup; Lee, Yoo Jin; Moon, Joon Ho; Lee, Je-Hwan | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea; Univ Ulsan, Asan Med Ctr, Dept Hematol, Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ, Dept Hematol & Oncol, Hwasun Hosp, Hwasun, South Korea; Keimyung Univ, Dongsan Med Ctr, Dept Hematol & Oncol, Sch Med, Daegu, South Korea; Korea Univ, Dept Internal Med, Div Hematol Oncol, Coll Med, Seoul, South Korea; Natl Canc Ctr, Ctr Hematol Malignancy, Dept Hematol Oncol, Goyang, South Korea; Inje Univ, Busan Paik Hosp, Dept Hematol & Oncol, Coll Med, Busan, South Korea; Dong A Univ, Div Hematol Oncol, Dept Internal Med, Coll Med, Busan, South Korea; Kosin Univ, Gospel Hosp, Dept Internal Med, Div Hematol Oncol,Coll Med, Busan, South Korea; Univ Ulsan, Ulsan Univ Hosp, Div Hematol Oncol, Coll Med, Ulsan, South Korea | Lee, Yoojin/AAB-9799-2022; LEE, SEOK-YONG/A-8012-2012; Lee, Jeong-Hoon/Q-1055-2018 | 57191874272; 56175730000; 13310226800; 56955900700; 55712969800; 22984055900; 8960168300; 57222279178; 35268272400; 55556573100; 56547959500; 57218103550; 57188669696; 56568642700; 16637544900 | jhmoon@knu.ac.kr; | KOREAN JOURNAL OF INTERNAL MEDICINE | KOREAN J INTERN MED | 1226-3303 | 2005-6648 | 38 | 5 | SCIE | MEDICINE, GENERAL & INTERNAL | 2023 | 2.2 | 28.1 | 1.47 | 2025-06-25 | 8 | 9 | Survival; Leukemia; acute lymphoblastic; Rituximab | DOSE-INTENSIVE REGIMEN; HYPER-CVAD; PROGNOSTIC-SIGNIFICANCE; CD20 EXPRESSION; LYMPHOMA; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; MULTICENTER; RESISTANCE | Leukemia, acute lymphoblastic; Rituximab; Survival | Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Rituximab; alanine aminotransferase; amylase; asparaginase; aspartate aminotransferase; CD20 antigen; cytarabine; daunorubicin; etoposide; folinic acid; imatinib; mercaptopurine; methotrexate; prednisolone; rituximab; vincristine; antineoplastic agent; rituximab; acute lymphoblastic leukemia; acute pancreatitis; adolescent; adult; aged; alanine aminotransferase blood level; allogeneic hematopoietic stem cell transplantation; amylase blood level; anaphylaxis; Article; aspartate aminotransferase blood level; bacteremia; bone marrow; brain hemorrhage; cancer chemotherapy; cancer growth; cancer prognosis; cancer regression; chill; constipation; continuous infusion; controlled study; dosage schedule comparison; drug blood level; drug safety; edema; febrile neutropenia; female; follow up; hazard ratio; headache; human; human cell; hyperbilirubinemia; ileus; infection; infusion related reaction; leukemia cell line; leukemic blast cell; lung infection; major clinical study; male; middle aged; multicenter study; multiple cycle treatment; nausea and vomiting; oral mucositis; overall survival; peripheral neuropathy; phase 2 clinical trial; Philadelphia chromosome negative cell; Philadelphia chromosome positive cell; prospective study; rash; recurrence free survival; side effect; thorax pain; treatment outcome; treatment response; young adult; acute lymphoblastic leukemia; clinical trial; hematopoietic stem cell transplantation; Philadelphia 1 chromosome; remission | English | 2023 | 2023-09 | 10.3904/kjim.2022.401 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication | Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this study, we evaluated the efficacy of a tegoprazan-based, nonbismuth-containing quadruple (concomitant) therapy for the primary eradication of Helicobacter pylori. Methods: We conducted a prospective, single-arm, single-center, primitive study to verify the efficacy of a 10-day tegoprazan-based (50-mg dose) concomitant therapy, including amoxicillin (1,000-mg dose), clarithromycin (CLA; 500-mg dose), and metronidazole (MET; 500-mg dose) twice daily as a first-line treatment for H. pylori eradication. Results: We tested consecutive cultures for antibiotic susceptibility and minimum inhibitory concentrations. We enrolled 84 participants; 79 (94.0%) completed first-line therapy. The overall intention-to-treat and per-protocol eradication rates were 90.5% (95% confidence interval [CI], 82.1-95.8) and 96.2% (95% CI, 83.4-97.6), respectively. Of the 73 participants evaluated for antibiotic resistance, 19 (26.0%), 32 (42.5%), and 8 (11.0%) exhibited CLA, MET, and CLA and MET dual resistance, respectively. Of these, 39 participants (66.1%) exhibited successful eradication after the therapeutic regimen despite antibiotic resistance. Conclusions: The 10-day tegoprazan-based concomitant therapy may be an effective first-line treatment for eradicating H. pylori. | Kwon, Yong Hwan; Jeon, Seong Woo; Nam, Su Youn; Lee, Dong Wook; Park, Ji Hey; Bae, Hui Jin | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, 807 Hoguk Ro, Daegu 41404, South Korea | ; Jeon, Seongwoo/AAU-4618-2020 | 55775556800; 9733636500; 55617028500; 57202974895; 57208224008; 58478462100 | tear1480@hanmail.net; | KOREAN JOURNAL OF INTERNAL MEDICINE | KOREAN J INTERN MED | 1226-3303 | 2005-6648 | 38 | 4 | SCIE | MEDICINE, GENERAL & INTERNAL | 2023 | 2.2 | 28.1 | 1.15 | 2025-06-25 | 4 | 7 | Helicobacter pylori; Antibiotic resistance; Clarithromycin; Metronidazole; Tegoprazan | COMPETITIVE ACID BLOCKER; TRIPLE THERAPY; BISMUTH QUADRUPLE; VONOPRAZAN; INFECTION | Antibiotic resistance; Clarithromycin; Helicobacter pylori; Metronidazole; Tegoprazan | Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Prospective Studies; Treatment Outcome; amoxicillin; clarithromycin; levofloxacin; metronidazole; tegoprazan; tetracycline; amoxicillin; antiinfective agent; clarithromycin; metronidazole; tegoprazan; adult; antibiotic resistance; antibiotic sensitivity; Article; bacterium culture; confidence interval; controlled study; diarrhea; disease eradication; drug efficacy; drug safety; female; Helicobacter infection; Helicobacter pylori; histopathology; human; intention to treat analysis; liver function; major clinical study; male; minimum inhibitory concentration; nausea; nonhuman; open study; physical examination; prospective study; rhinopharyngitis; side effect; urticaria; vomiting; combination drug therapy; Helicobacter infection; Helicobacter pylori; treatment outcome | English | 2023 | 2023-07 | 10.3904/kjim.2022.345 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | A different PET test: The relationship between pet ownership and peritonitis risk in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) | Pet ownership is common around the world, with pet ownership increasing in many countries. Current guidelines are not supportive of pet ownership for peritoneal dialysis (PD) patients. We examined the association between ownership of cats and dogs and the incidence of peritonitis among PD patients participating in the prospective, observational Peritoneal Dialysis Outcomes and Practice Patterns Study. A total of 3655 PD patients from eight different countries was included, with a median follow-up of 14 months and a total exposure time of 55,475 patient-months. There were 1347 peritonitis episodes with an overall peritonitis rate of 0.29 episodes per patient year. There was no significant increased risk of peritonitis with any type of pet ownership, adjusted hazard ratio (HR) of 1.09 (95% confidence interval (95% CI): 0.96-1.25). However, patients who owned both cats and dogs had an increased risk of peritonitis compared to patients without pets, HR = 1.45 (95% CI: 1.14-1.86). These results suggest that there is no increased risk of peritonitis with pet ownership except for those with both cats and dogs. This information should not prevent PD patients from owning pets but may be helpful for PD patients and their care team to direct training to minimise the risk of peritonitis. | Boudville, Neil; McCullough, Keith; Bieber, Brian; Pisoni, Ronald; Kanjanabuch, Talerngsak; Kawanishi, Hideki; Kim, Yong-Lim; Wilkie, Martin; Nitta, Kosaku; Piraino, Beth; Teitelbaum, Isaac; Perl, Jeffrey | Univ Western Australia, Med Sch, Perth, WA, Australia; Arbor Res Collaborat Hlth, Ann Arbor, MI USA; Chulalongkorn Univ, Ctr Excellence Kidney Metab Disorders, Bangkok, Thailand; Chulalongkorn Univ, Dept Med, Div Nephrol, Bangkok, Thailand; Tsuchiya Gen Hosp, Hiroshima, Japan; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Sheffield Teaching Hosp, Sheffield, S Yorkshire, England; Japanese Soc Dialysis Therapy, Div Renal Data Registry, Tokyo, Japan; Tokyo Womens Med Univ, Dept Nephrol, Tokyo, Japan; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Univ Colorado Hosp, Aurora, CO USA; Univ Toronto, St Michaels Hosp, Toronto, ON, Canada | ; Kim, Yong-Lim/AGK-3172-2022; Perl, Jeffrey/HKW-4066-2023; Boudville, Neil/H-8864-2014 | 57190234695; 57197188719; 53982698300; 7004217145; 13609834900; 7103248513; 55633533600; 7005667826; 57204421420; 7006682882; 57204346479; 57192120457 | neil.boudville@uwa.edu.au; | PERITONEAL DIALYSIS INTERNATIONAL | PERITON DIALYSIS INT | 0896-8608 | 1718-4304 | 43 | 3 | SCIE | UROLOGY & NEPHROLOGY | 2023 | 2.7 | 28.2 | 0.91 | 2025-06-25 | 4 | 4 | PDOPPS; peritoneal dialysis; peritonitis; pet ownership | COMPANION ANIMALS | PDOPPS; peritoneal dialysis; peritonitis; pet ownership | Animals; Cats; Dogs; Ownership; Peritoneal Dialysis; Peritonitis; Positron-Emission Tomography; Prospective Studies; animal experiment; animal model; Article; Campylobacter; Capnocytophaga; cat; confidence interval; dialysis; dog; Escherichia coli; hazard ratio; Neisseria; nonhuman; organization and management; outcome assessment; Pasteurella; Pasteurella multocida; peritoneal dialysis; Peritoneal Dialysis Outcomes and Practice Patterns Study; peritonitis; proportional hazards model; prospective study; questionnaire; risk; Staphylococcus; zoonosis; animal; peritonitis; positron emission tomography | English | 2023 | 2023-05 | 10.1177/08968608221144450 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Association between sclerostin levels and vascular outcomes in kidney transplantation patients | Background The impact of circulating sclerostin levels on vascular calcification has shown conflicting results depending on the target population and vascular anatomy. This study investigated the associations of sclerostin levels with vascular outcomes in kidney transplant patients. Methods In a prospective observational study of the Korean Cohort Study for Outcome in Patients with Kidney Transplantation, 591 patients with serum sclerostin level data prior to transplantation were analyzed. The main predictor was the pre-transplant sclerostin level. Vascular outcomes were the abdominal aortic calcification score and brachial-ankle pulse wave velocity measured at pre-transplant screening and three and five years after kidney transplantation. Results In linear regression analysis, sclerostin level positively correlated with changes in abdominal aortic calcification score between baseline and five years after kidney transplantation (coefficient of 0.73 [95% CI, 0.11-1.35] and 0.74 [95% CI, 0.06-1.42] for second and third tertiles, respectively, vs the first tertile). In a longitudinal analysis over five years, using generalized estimating equations, the coefficient of the interaction (sclerostin x time) was significant with a positive value, indicating that higher sclerostin levels were associated with faster increase in post-transplant abdominal aortic calcification score. Linear regression analysis revealed a positive association between pre-transplant sclerostin levels and changes in brachial-ankle pulse wave velocity (coefficient of 126.7 [95% CI, 35.6-217.8], third vs first tertile). Moreover, a significant interaction was identified between sclerostin levels and brachial-ankle pulse wave velocity at five years. Conclusions Elevated pre-transplant sclerostin levels are associated with the progression of post-transplant aortic calcifications and arterial stiffness. | Koh, Hee Byung; Ryu, Jung Hwa; Kim, Seung-seob; Kim, Myung-Gyu; Park, Jae Berm; Kim, Chan Duk; Kang, Kyung Pyo; Ro, Han; Han, Seung-Yeup; Huh, Kyu Ha; Yang, Jaeseok | Catholic Kwandong Univ, Int St Marys Hosp, Dept Internal Med, Incheon, South Korea; Ewha Womans Univ, Seoul Hosp, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Radiol, Seoul, South Korea; Korea Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Seoul Samsung Med Ctr, Dept Surg, Seoul, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Jeonbuk Natl Univ, Med Sch, Res Inst Clin Med, Dept Internal Med, Jeonju, South Korea; Gachon Univ, Gil Hosp, Dept Internal Med, Incheon, South Korea; Keimyung Univ, Dongsan Med Ctr, Dept Internal Med, Daegu, South Korea; Yonsei Univ, Coll Med, Severance Hosp, Dept Surg, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, 50-1 Yonsei ro, Seoul 03722, South Korea | ; Kang, Kyung Pyo/ABG-3614-2020; Han, Seung Seok/HGD-2825-2022; Yang, Jae/LUW-8250-2024 | 57212586672; 14621981000; 57194193410; 36183208900; 13605451500; 8558530700; 7402223564; 26538034700; 24281360600; 35183155900; 57212326527 | jcyjs@yuhs.ac; | JOURNAL OF NEPHROLOGY | J NEPHROL | 1121-8428 | 1724-6059 | 36 | 7 | SCIE | UROLOGY & NEPHROLOGY | 2023 | 2.7 | 28.2 | 0.45 | 2025-06-25 | 2 | 2 | Sclerostin; Abdominal aortic calcification; Arterial stiffness; Pulse wave velocity; Kidney transplantation | CORONARY-ARTERY CALCIFICATION; SERUM SCLEROSTIN; CIRCULATING SCLEROSTIN; CARDIOVASCULAR EVENTS; MORTALITY; DISEASE; BONE; PROGRESSION; STIFFNESS; INHIBITORS | Abdominal aortic calcification; Arterial stiffness; Kidney transplantation; Pulse wave velocity; Sclerostin | Ankle Brachial Index; Cohort Studies; Genetic Markers; Humans; Kidney Transplantation; Pulse Wave Analysis; Vascular Calcification; Vascular Stiffness; 25 hydroxyvitamin D; albumin; antithrombocytic agent; basiliximab; beta adrenergic receptor blocking agent; calcineurin inhibitor; hydroxymethylglutaryl coenzyme A reductase inhibitor; mycophenolic acid; parathyroid hormone; sclerostin; thymocyte antibody; vitamin D; abdominal aorta; adult; aortic calcification; arterial stiffness; Article; blood vessel calcification; brachial-ankle pulse wave velocity; cohort analysis; coronary artery disease; diastolic blood pressure; end stage renal disease; estimated glomerular filtration rate; female; graft survival; human; kidney graft; kidney transplantation; longitudinal study; major clinical study; male; observational study; peritoneal dialysis; systolic blood pressure; ankle brachial index; arterial stiffness; blood vessel calcification; genetic marker; procedures; pulse wave | English | 2023 | 2023-09 | 10.1007/s40620-023-01732-7 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study | Background: We aimed to evaluate the current status of first-line treatment options for prostate cancer in patients aged >= 75 years in Korea. Materials and methods: The study included 873 patients diagnosed with biopsy-proven prostate cancer at 5 institutions in Korea from January 2009 to December 2018. Inclusion criteria were aged >= 75 years at diagnosis, prostate biopsy with >= 12 cores, and follow-up period >= 1 year. Clinical data were retrospectively collected from electronic medical records. Results: Primary treatment for prostate cancer in patients aged >= 75 years included androgen depri-vation therapy (ADT) (n = 614), radical prostatectomy (RP) (n = 114), and radiation therapy (n = 62). Among patients with RP, nine patients received ADT before RP. The RP group was younger with better Eastern Cooperative Oncology Group Performance Status (ECOG PS), lower initial prostate-specific an-tigen (PSA), Gleason score (GS), max percent positive cores, less positive cores, and less advanced clinical Tumor Node Metastasis (TNM) stage compared with the ADT group. Multivariate analysis showed that age, ECOG PS, and PSA were independent prognostic factors for RP. When the ADT group was classified by therapeutic regimens, the most common therapeutic regimen was maximal androgen blockade (MAB) (n = 571), and leuprolide + bicalutamide (n = 330) was the most common MAB regimen. Multivariate analysis for secondary treatment showed that age, ECOG PS, GS, and clinical N1 or M1 stage were in-dependent predictive factors. Enzalutamide was the most preferred treatment for tertiary treatment. Conclusion: In patients with prostate cancer aged >= 75 years, the most common treatment option was MAB, and the leuprolide + bicalutamide was the most common MAB regimen. Age, ECOG PS, and PSA are the useful indicators of surgical treatment, which increased during the study period. Younger patients with high GS and advanced clinical stage were more likely to undergo secondary treatment. (c) 2022 Asian Pacific Prostate Society. Publishing services by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | Park, Dong Jin; Kang, Ho Won; Kwon, Se Yun; Seo, Young Jin; Lee, Kyung Seop; Kim, Byung Hoon; Shin, Teak Jun; Kim, Won Tae; Kim, Yong -June; Yun, Seok Joong; Lee, Sang-Cheol; Chung, Jae-Wook; Choi, Seock Hwan; Lee, Jun Nyung; Kim, Hyun Tae; Kim, Tae-Hwan; Yoo, Eun Sang; Kwon, Tae Gyun; Jung, Wonho; Ha, Yun-Sok | Dongguk Univ, Dept Urol, Coll Med, Gyeongju, South Korea; Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Dept Urol, Cheongju, South Korea; Keimyung Univ, Gyeongju Dongsan Hosp, Dept Urol, Sch Med, Gyeongju, South Korea; Keimyung Univ, Sch Med, Dept Urol, Dongsan Hosp, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Urol, 807 Hoguk Ro, Daegu, South Korea; Keimyung Univ, Sch Med, Dept Urol, Dongsan Hosp, 1035 Dalgubeol Daero, Daegu 42601, South Korea | Kim, Young-Bo/AAR-8052-2021; Kim, Byung-Hoon/AFB-5417-2022; Lee, Sang/E-4151-2012; Lee, Dong Hyun/AAD-5566-2021; Kim, Siwon/KHX-9078-2024; Kim, Yong-June/E-5622-2012; Kim, Kyu/E-7814-2012; Kim, Tae/B-9921-2013 | 57220636322; 35757703900; 35995613300; 58727985400; 35313516400; 57203500751; 55192758100; 57203514393; 26422204800; 16302421300; 57218216917; 35204798500; 9742645500; 16301364600; 55739531300; 57797823600; 7006609239; 15073765400; 56150089500; 35487226400 | wjung@dsmc.or.kr;yunsokha@gmail.com; | PROSTATE INTERNATIONAL | PROSTATE INT | 2287-8882 | 2287-903X | 11 | 1 | SCIE | UROLOGY & NEPHROLOGY | 2023 | 2.7 | 28.2 | 1.69 | 2025-06-25 | 5 | 6 | Aging; Prostate Cancer; Treatment | ASSISTED RADICAL PROSTATECTOMY; MEN | Aging; Prostate Cancer; Treatment | abiraterone; antiandrogen; bicalutamide; docetaxel; enzalutamide; leuprorelin; prostate specific antigen; aged; androgen deprivation therapy; Article; body mass; cancer chemotherapy; cancer diagnosis; cancer patient; cancer prognosis; cancer radiotherapy; cancer staging; cancer surgery; clinical evaluation; clinical feature; clinical study; comparative study; controlled study; ECOG Performance Status; electronic medical record; follow up; Gleason score; human; Korean (people); major clinical study; male; positivity rate; predictive value; prostate biopsy; prostate cancer; prostate volume; prostatectomy; retrospective study | English | 2023 | 2023-03 | 10.1016/j.prnil.2022.08.003 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | High-resolution surface mass loads in the Amazon Basin combining GRACE and river routing model | Understanding water redistribution on Earth's surface is essential to hydrological applications and water management. Variations in water mass loads have been observed by the Gravity Recovery and Climate Experiment (GRACE), but the low spatial resolution of GRACE limits determination of their distribution in detail. Hydrologic models provide higher spatial resolution water mass loads, but may include larger uncertainties. In this study, we develop high-resolution surface mass loads over the Amazon basin using forward modelling by combining GRACE data and a hydrologic model. River routing discharge is also included as a priori information because of the large water volume changes on relatively narrow channels in the Amazon basin. These high-resolution surface mass loads constrained by river routing agree with GRACE observations when spatially smoothed. Vertical deformation estimated from these high-resolution loads agree with Global Navigation Satellite System (GNSS) observations, at both seasonal and inter-annual timescales. In particular the most improved agreement is obtained at the NAUS GNSS station, close to the main channel of the Amazon, relative to predictions made using GRACE data. At two other stations (APSA and MAPA) near the main channel, the estimated vertical deformations apparently differ from observation, but much of the discrepancy is reduced when river path is corrected in river-routing model, indicating the importance of water loads on river channel to understand crustal displacement in the area. | Youm, Kookhyoun; Eom, Jooyoung; Seo, Ki-Weon; Chen, Jianli; Wilson, Clark R.; Oh, Seokhoon | Seoul Natl Univ, Dept Earth Sci Educ, Seoul 08826, South Korea; Kyungpook Natl Univ, Dept Earth Sci Educ, Daegu 41566, South Korea; Seoul Natl Univ, Ctr Educ Res, Seoul 08826, South Korea; Hong Kong Polytech Univ, Dept Land Surveying & Geoinformat, Kowloon, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Res Inst Land & Space, Kowloon, Hong Kong, Peoples R China; Univ Texas Austin, Ctr Space Res, Austin, TX 78759 USA; Univ Texas Austin, Jackson Sch Geosci, Dept Geol Sci, Austin, TX 78712 USA; Kangwon Natl Univ, Dept Energy & Resources Engn, Gangwon 24341, South Korea | ; Seo, Ki-weon/AAH-7729-2021; Eom, Jooyoung/KBC-4439-2024; Chen, Jianli/KUD-8259-2024 | 57192693432; 36645970800; 8407160800; 57205523218; 7404896041; 16553124600 | eomjy@knu.ac.kr; | GEOPHYSICAL JOURNAL INTERNATIONAL | GEOPHYS J INT | 0956-540X | 1365-246X | 232 | 3 | SCIE | GEOCHEMISTRY & GEOPHYSICS | 2023 | 2.8 | 28.2 | 0.61 | 2025-06-25 | 5 | 3 | Loading of the Earth; Satellite geodesy; Satellite gravity; Time variable gravity; Transient deformation; South America; GNSS; GRACE | TOTAL WATER STORAGE; VERTICAL DEFORMATION; CONTINENTAL WATER; SPATIAL SCALES; GRAVITY-FIELD; GPS; EARTH; CALIFORNIA; MOTION; DISPLACEMENTS | GNSS; GRACE; Loading of the Earth; Satellite geodesy; Satellite gravity; South America; Time variable gravity; Transient deformation | Amazon Basin; Geodetic satellites; Global positioning system; Gravitation; Image resolution; Water management; Global Navigation Satellite Systems; Gravity recovery and climate experiments; High resolution; Loading of the earth; Satellite geodesy; Satellite gravity; South America; Surface mass loads; Time-variable gravity; Transient deformation; GNSS; GRACE; hydrological modeling; satellite data; spatial resolution; water management; water mass; Rivers | English | 2023 | 2023-11-22 | 10.1093/gji/ggac439 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure | Aims The long-term effect of angiotensin receptor-neprilysin inhibitor (ARNI) remains uncertain in patients who have experienced improvements in left ventricular (LV) systolic function or significant LV reverse remodelling following a certain period of treatment. It is also unclear how ARNI performs in patients who have not shown these improvements. This study aimed to assess the impact of prolonged ARNI use compared with angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with and without significant treatment response after 1 year of heart failure (HF) treatment. Methods and results The present study enrolled patients with HF with reduced ejection fraction (HFrEF) who were treated with either ARNI or ACEIs/ARBs within 1 year of undergoing index echocardiography. After 1 year of treatment, patients were reclassified into the following groups: (i) patients with HF with improved ejection fraction and persistent HFrEF and (ii) patients with and without LV reverse remodelling based on the follow-up echocardiography. The effect of ARNI versus that of ACEIs/ARBs in each group was assessed from the time of categorizing into new groups using the composite event of all-cause mortality and HF hospitalization. A total of 671 patients with HFrEF (age, 66.4 +/- 14.1 years; males, 66.8%) were included, and 133 (19.8%) composite events of death and rehospitalization for HF were observed during the follow-up (median follow-up, 44 [interquartile range, 34-51] months). ARNI had a significantly lower event rate than ACEIs/ARBs in patients with HF with improved ejection fraction (7.0% vs. 30.4%, P = 0.020) and those with persistent HFrEF (17.6% vs. 49.7%, P < 0.001). Irrespective of whether patients exhibited LV reverse remodelling (15.8% vs. 31.1%, P = 0.001) or not (15.0% vs. 54.9%, P < 0.001), ARNIs were associated with a significantly lower event rate than ACEIs/ARBs. Conclusions Regardless of significant treatment response measured by either LVEF or LV reverse remodelling after 1 year of treatment, the extended utilization of ARNI demonstrated a more favourable prognosis than that of ACEIs/ARBs in patients with HFrEF. | Park, Hyuk Kyoon; Park, Jong Sung; Kim, Myeong Seop; Lee, Eunkyu; Choi, Hyohun; Park, Yoon Jung; Park, Bo Eun; Kim, Hong Nyun; Kim, Nam Kyun; Bae, Myung Hwan; Lee, Jang Hoon; Park, Hun Sik; Cho, Yongkeun; Jang, Se Yong; Yang, Dong Heon | Daegu Fatima Hosp, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Dept Internal Med, 807, Hoguk-ro, Buk-gu, Daegu 41404, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, 130, Dongdeok-ro, Daegu 41944, South Korea | Park, Hang-soo/AEH-1640-2022 | 57221712499; 58363053000; 57371425600; 57722787900; 57723256300; 57216539556; 57201131446; 56706769800; 55887032700; 36607356800; 54581258000; 57198844106; 9249593500; 57207977889; 35277423400 | seyongjang@knu.ac.kr;ddhyang@knu.ac.kr; | ESC HEART FAILURE | ESC HEART FAIL | 2055-5822 | 10 | 6 | SCIE | CARDIAC & CARDIOVASCULAR SYSTEMS | 2023 | 3.2 | 28.2 | 0.37 | 2025-06-25 | 2 | 2 | Angiotensin receptor-neprilysin inhibitor; Heart failure with improved ejection fraction; Heart failure with reduced; ejection fraction; Reverse remodelling | CONVERTING-ENZYME-INHIBITORS; DILATED CARDIOMYOPATHY; MORTALITY; MORBIDITY; ENALAPRIL; TRIAL; CARVEDILOL; METOPROLOL; MANAGEMENT; WITHDRAWAL | Angiotensin receptor–neprilysin inhibitor; Heart failure with improved ejection fraction; Heart failure with reduced ejection fraction; Reverse remodelling | Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Treatment Outcome; angiotensin receptor antagonist; angiotensin receptor neprilysin inhibitor; dipeptidyl carboxypeptidase inhibitor; enkephalinase inhibitor; unclassified drug; angiotensin receptor antagonist; antihypertensive agent; dipeptidyl carboxypeptidase inhibitor; membrane metalloendopeptidase; age; aged; all cause mortality; Article; death; drug response; echocardiography; female; follow up; gender; heart failure with reduced ejection fraction; heart ventricle remodeling; hospital readmission; hospitalization; human; major clinical study; male; patient coding; treatment duration; heart failure; heart stroke volume; middle aged; physiology; treatment outcome; very elderly | English | 2023 | 2023-12 | 10.1002/ehf2.14505 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer | Background: This study aimed to evaluate the treatment outcomes and define the prostate-specific antigen (PSA) kinetics as potential prognostic factors in patients with intermediate- or high-risk localized prostate cancer (PCa) who underwent moderately hypofractionated radiation therapy. Methods: The study retrospectively reviewed the medical records of 149 patients with intermediate- or high-risk localized PCa who underwent definitive radiation therapy (70 Gy in 28 fractions) without androgen deprivation therapy. Clinical outcomes were analyzed based on risk stratification (favorable-intermediate, unfavorable-intermediate, and high-risk). The biochemical failure rate (BFR) and clinical failure rate (CFR) were stratified based on the PSA nadir and the time to the PSA nadir to identify the prognostic effect of PSA kinetics. Acute and late genitourinary and gastrointestinal adverse events were analyzed. Results: Significant differences were observed in the BFR and CFR according to risk stratification. No recurrence was observed in the favorable intermediate-risk group. The 7-year BFR and CFR for the unfavorable intermediate-risk and high-risk groups were 19.2% and 9.8%, and 31.1% and 25.3%, respectively. Patients with a PSA nadir >0.33 ng/mL or a time to the PSA nadir <36 months had a significantly greater BFR and CFR. The crude rate of grade 3 late adverse events was 3.4% (genitourinary: 0.7%; gastrointestinal: 2.7%). No grade 4-5 adverse event was reported. Conclusion: A significant difference in clinical outcomes was observed according to risk stratification. The PSA nadir and time to the PSA nadir were strongly associated with the BFR and CFR. Therefore, PSA kinetics during follow-up are important for predicting prognosis. (c) 2023 The Asian Pacific Prostate Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Lee, Tae Hoon; Pyo, Hongryull; Yoo, Gyu Sang; Lee, Hyun Moo; Jeon, Seong Soo; Seo, Seong Il; Jeong, Byong Chang; Jeon, Hwang Gyun; Sung, Hyun Hwan; Kang, Minyong; Song, Wan; Chung, Jae Hoon; Bae, Bong Kyung; Park, Won | Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea; Kyungpook Natl Univ, Dept Radiat Oncol, Chilgok Hosp, Daegu, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiat Oncol, Sch Med, 81 Irwon Ro,Gangnam Gu, Seoul 06351, South Korea | Lee, Kyoungbun/F-6358-2011; sung, hh/O-6246-2014; Yoo, Gyu Sang/IUP-1304-2023; Lee, Tae Hoon/ABB-2997-2021; Cho, Jae/Y-8474-2019; 서, 성일/HPD-3967-2023 | 57216507584; 55655325100; 57060003400; 50262117000; 7203005276; 7202469835; 7102237943; 7201833627; 16203908200; 23489077600; 56079751200; 59674240400; 57191481610; 55663053400 | wonro.park@samsung.com; | PROSTATE INTERNATIONAL | PROSTATE INT | 2287-8882 | 2287-903X | 11 | 3 | SCIE | UROLOGY & NEPHROLOGY | 2023 | 2.7 | 28.2 | 0.84 | 2025-06-25 | 2 | 3 | Adverse events; Prostate cancer; Prostate-specific antigen; Radiation therapy | EXTERNAL-BEAM RADIOTHERAPY; ANDROGEN SUPPRESSION; RANDOMIZED-TRIAL; DEPRIVATION; IRRADIATION; CONSENSUS; DURATION; EORTC | Adverse events; Prostate cancer; Prostate-specific antigen; Radiation therapy | prostate specific antigen; adult; aged; androgen deprivation therapy; Article; biochemical recurrence; cancer localization; cancer specific survival; clinical outcome; Common Terminology Criteria for Adverse Events; controlled study; ECOG Performance Status; follow up; gastrointestinal disease; Gleason score; high risk population; human; hypofractionated radiotherapy; intermediate risk population; kinetics; major clinical study; male; overall survival; prostate cancer; proton therapy; radiodiagnosis; retrospective study; treatment outcome; urogenital tract disease | English | 2023 | 2023-09 | 10.1016/j.prnil.2023.07.002 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Acceleration of NO2 gas sensitivity in two-dimensional SnSe2 by Br doping | The authors report a Br doping effect on the NO2 gas sensing properties of a two-dimensional (2D) SnSe2 semiconductor. Single crystalline 2D SnSe2 samples with different Br contents are grown by a simple melt-solidification method. By analyzing the structural, vibrational as well as electrical properties, it can be confirmed that the Br impurity substitutes on the Se-site in SnSe2 serving as an efficient electron donor. When we measure the change of resistance under a 20 ppm NO2 gas flow condition at room temperature, both responsivity and response time are drastically improved by Br doping from 1.02% and 23 s to 3.38% and 15 s, respectively. From these results, it can be concluded that Br doping plays a key role for encouraging the charge transfer efficiency from the SnSe2 surface to the NO2 molecule by elaborating Fermi level in 2D SnSe2. | Choi, Myung Sik; Bang, Geukchan; Lee, Jeongmin; Kim, Inseo; Bang, Joonho; Lee, Seung Yong; Lee, Kimoon; Lee, Kyu Hyoung | Kyungpook Natl Univ, Sch Nano & Mat Sci & Engn, Sangju 37224, South Korea; Kunsan Natl Univ, Dept Phys, Gunsan 54150, South Korea; Gyeongsang Natl Univ, Sch Mat Sci & Engn, Jinju 52828, South Korea; Yonsei Univ, Dept Mat Sci & Engn, Seoul 03722, South Korea; Yonsei Univ, KIURI Inst, Seoul 03722, South Korea | Bang, Joonho/AFZ-9712-2022; Lee, KiMoon/D-3825-2011; Choi, Myung-Sik/J-5687-2012 | 57190737942; 57215188660; 57934137200; 57981293800; 56168055600; 57436380000; 57222518881; 35205856800 | kimoon.lee@kunsan.ac.kr;khlee2018@yonsei.ac.kr; | DALTON TRANSACTIONS | DALTON T | 1477-9226 | 1477-9234 | 52 | 11 | SCIE | CHEMISTRY, INORGANIC & NUCLEAR | 2023 | 3.5 | 28.4 | 0.48 | 2025-06-25 | 3 | 3 | PERFORMANCE | Charge transfer; Nitrogen oxides; Semiconducting selenium compounds; Semiconducting tin compounds; Semiconductor doping; Doping effects; Electron donors; Gas flow conditions; Gas sensing properties; Gas sensitivity; Melt solidification; Responsivity; Simple++; Single-crystalline; Two-dimensional; Flow of gases | English | 2023 | 2023-03-14 | 10.1039/d2dt03784j | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Bilobetin induces apoptosis in human hepatocellular carcinoma cells via ROS level elevation and inhibition of CYP2J2 | Bilobetin is a biflavonoid isolated from the leaves of Ginkgo biloba. Bilobetin displays several biological effects, however, the activities of bilobetin against cancer have been solely demonstrated. Thus, the aim of this study is investigating the apoptotic effects of and anticancer mechanism of bilobetin in Huh7 and HepG2 cells, both of human hepatocellular carcinoma (HCC) cell lines. MTT, cell counting, and colony formation assay showed that anti-proliferation effect of bilobetin. Cell cycle analysis revealed that bilobetin induces increase of population of the sub G1 phase. Annexin V/PI staining and TUNEL assay showed that bilobetin treatment promotes apoptotic cell death and DNA fragmentation. Bilobetin also induces ROS elevation and DNA damage in HCC cells. Western blot analysis elucidated that bilobetin displays apoptotic signaling pathway in HCC cells via upregulating cleaved PARP, cleaved caspase3 and Bax and downregulating CYP2J2. Bilobetin inhibited CYP2J2-catalyzed terfenadine and ebastine hydroxylase activities with IC50 values of 0.81 and 2.21 mu M, respectively. Transfection of CYP2J2 siRNA increased the anticancer effect of bilobetin in HCC cells through the inhibition of CYP2J2 expression. Taken together, this study suggests that bilobetin induces apoptosis against HCC cells via ROS level elevation and inhibition of CYP2J2. (C) 2023 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Lee, Han Ki; Bae, Subin; Lee, Jongsung; Cha, Hyo Sun; Nam, Myeong Jin; Lee, Jongbok; Park, Kyungmoon; Yang, Yung-Hun; Jang, Kyu Yun; Liu, Kwang-Hyeon; Park, See-Hyoung | Gachon Univ, Dept Biol Sci, Seongnam 13120, South Korea; Kyungpook Natl Univ, Coll Pharm, FOUR Community Based Intelligent Novel Drug Discov, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu 41566, South Korea; Sungkyunkwan Univ, Dept Integrat Biotechnol, Suwon 16419, South Korea; Hongik Univ, Dept Bio & Chem Engn, Sejong 30016, South Korea; Konkuk Univ, Dept Biol Engn, Seoul 05029, South Korea; Jeonbuk Natl Univ, Med Sch, Dept Pathol, Jeonju 54896, South Korea; Jeonbuk Natl Univ, Res Inst Clin Med, Jeonju 54896, South Korea; Jeonbuk Natl Univ Hosp, Biomed Res Inst, Jeonju 54896, South Korea | 58478137000; 57224532908; 12800238500; 58478004400; 7006081545; 57187423600; 57207108900; 9334560800; 55861562700; 55768214700; 7501838385 | kyjang@jbnu.ac.kr;dstlkh@knu.ac.kr;shpark74@hongik.ac.kr; | ARABIAN JOURNAL OF CHEMISTRY | ARAB J CHEM | 1878-5352 | 1878-5379 | 16 | 9 | SCIE | CHEMISTRY, MULTIDISCIPLINARY | 2023 | 5.3 | 28.4 | 0.41 | 2025-06-25 | 4 | 4 | Bilobetin; CYP2J2; Hepatocellular carcinoma; Apoptosis; Anticancer; Reactive oxygen species | CYTOCHROME-P450 2J2; DEATH; PROLIFERATION; VIABILITY; BIOMARKER; PROMOTES | Anticancer; Apoptosis; Bilobetin; CYP2J2; Hepatocellular carcinoma; Reactive oxygen species | Cell culture; Cell signaling; Electrophoresis; Molecular biology; Oxygen; Anti-cancer mechanism; Anticancer; Apoptotic effects; Bilobetin; Biological effects; CYP2J2; Ginkgo biloba; Hepatocellular carcinoma; Hepatocellular carcinoma cell; Reactive oxygen species; Cell death | English | 2023 | 2023-09 | 10.1016/j.arabjc.2023.105094 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia | Purpose We evaluated the characteristics of CCAAT/enhancer-binding protein & alpha; (CEBPA) mutations and the significance of a basic leucine zipper in-frame mutation (bZIPin-f) of CEBPA in patients with acute myeloid leukemia with a normal karyotype. Materials and Methods Based on updated knowledge of CEBPA mutations, we conducted next-generation sequencing analyses in a previously established real-world cohort. Results Among 78 of a total of 395 patients (19.7%), 50 had bZIPin-f CEBPA, and 28 had non-bZIPin-f CEBPA. In the multivariate analysis, patients with NPM1mut, those with bZIPin-f CEBPA, and those who underwent allogeneic hematopoietic cell transplantation (allo-HCT) had favorable overall survival (OS), but FLT3-ITDmut was a poor prognostic indicator. For relapse-free survival (RFS) and cumulative incidence of relapse, bZIPin-f CEBPA, and allo-HCT were associated with favorable outcomes; FLT3-ITDpos was associated with worse outcomes. In the CEBPA double-mutated group (CEBPAdm), bZIPin-f CEBPA was associated with superior outcomes in terms of OS (p=0.007) and RFS (p=0.007) compared with non-bZIPin-f CEBPA. Of 50 patients with bZIPin-f CEBPA, 36 patients had at least one mutation. When grouped by the presence of mutations in chromatic/DNA modifiers (C), cohesion complex (C), and splicing genes (S) (CCS mutations), CCS-mutated bZIPin-f CEBPA was associated with poor OS (p=0.044; hazard ratio [HR], 2.419) and a trend in inferior RFS (p=0.186; HR, 1.838).Conclusion Only bZIPin-f CEBPA was associated with favorable outcomes in patients with CEBPAdm. However, some mutations accom-panying bZIPin-f CEBPA showed inferior OS; thus, further studies with larger numbers of patients are required for clear conclusions of the significance of bZIPin-f CEBPA. | Ahn, Seo-Yeon; Kim, TaeHyung; Kim, Mihee; Song, Ga-Young; Jung, Sung-Hoon; Yang, Deok-Hwan; Lee, Je-Jung; Kim, Mi Yeon; Jung, Chul Won; Jang, Jun-Ho; Kim, Hee Je; Moon, Joon Ho; Sohn, Sang Kyun; Won, Jong -Ho; Kim, Sung-Hyun; Kim, Hyeoung-Joon; Ahn, Jae-Sook; Kim, Dennis Dong Hwan | Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, 322 Seoyang Ro, Hwasun 58128, South Korea; Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada; Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; Chonnam Natl Univ, Genom Res Ctr Hematopoiet Dis, Hwasun Hosp, Hwasun, South Korea; Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Canc Res Inst, Coll Med,Dept Hematol, Seoul, South Korea; Kyungpook Natl Univ Hosp, Dept Hematol Oncol, Daegu, South Korea; Soon Chun Hyang Univ Hosp, Dept Hematol Oncol, Seoul, South Korea; Dong A Univ, Dept Hematol Oncol, Coll Med, Busan, South Korea; Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada | Kim, Dennis/AAH-8499-2019; Park, Jung Hyun/HJA-3755-2022; Kim, Tae/O-4252-2015; Lee, Sang-Jun/A-3892-2015; Kim, Chang Gon/IAP-6721-2023; Lee, Jung-Hye/F-6974-2013; Kim, Hyung Joon/ABD-3143-2020; Won, Jongho/AAM-8322-2021 | 55945078500; 55763792349; 57218694093; 57193027251; 55511978300; 8701758000; 7601478211; 57904806900; 56405934800; 56470133700; 7410130758; 56568642700; 13310226800; 26434081600; 56547959500; 7410127473; 22984055900; 56312200900 | f0115@jnu.ac.kr; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 3 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 0.91 | 2025-06-25 | 5 | 6 | Leukemia; Myeloid; Acute; CEBPA; Next-generation sequencing; Allogeneic transplantation | FAVORABLE PROGNOSIS; MUTATIONS; AML | Acute; Allogeneic transplantation; CEBPA; Leukemia; Myeloid; Next-generation sequencing | CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Proteins; Clinical Relevance; Disease-Free Survival; Humans; Karyotype; Leukemia, Myeloid, Acute; Mutation; Nucleophosmin; Prognosis; basic leucine zipper transcription factor; CCAAT enhancer binding protein alpha; CD135 antigen; genomic DNA; leucine zipper protein; nucleophosmin; CCAAT enhancer binding protein; CEBPA protein, human; nucleophosmin; acute myeloid leukemia; adult; allogeneic hematopoietic stem cell transplantation; allotransplantation; Article; bone marrow; cancer patient; cancer prognosis; cancer recurrence; cancer survival; clinical significance; comparative study; consolidation chemotherapy; controlled study; cumulative incidence; date of death; female; follow up; gene frequency; gene mutation; hematopoietic cell; high throughput sequencing; human; induction chemotherapy; major clinical study; male; outcome assessment; overall survival; polymerase chain reaction; recurrence free survival; RNA splicing; Sanger sequencing; treatment outcome; acute myeloid leukemia; clinical significance; disease free survival; genetics; karyotype; mutation; prognosis | English | 2023 | 2023-07 | 10.4143/crt.2022.1407 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response | Purpose Even though pazopanib, a multitargeted tyrosine kinase inhibitor, has been approved for refractory soft tissue sarcoma (STS), little is known about the molecular determinants of the response to pazopanib. We performed integrative molecular characteri-zation to identify potential predictors of pazopanib efficacy. Materials and Methods We obtained fresh pre-treatment tumor tissue from 35 patients with advanced STS receiving pazopanib-based treatment. Among those, 18 (51.4%) received pazopanib monotherapy, and the remaining 17 (48.6%) received pazopanib in combination with durvalumab, programmed death-ligand 1 blockade. Whole-exome and transcriptome sequencing were performed for each tumor and patient germline DNA. Results Of the 35 patients receiving pazopanib-based treatment, nine achieved a partial response (PR), resulting in an objective response rate (ORR) of 27.3%, and the median progression-free survival (PFS) was 6.0 months. Patients with CDK4 amplification (copy ratio tumor to normal > 2) exhibited shorter PFS (3.7 vs. 7.9 months, p=2.09x10-4) and a poorer response (ORR; 0% vs. 33.3%) compared to those without a gene amplification (copy ratio <= 2). Moreover, non-responders demonstrated transcriptional activation of CDK4 via DNA amplification, resulting in cell cycle activation. In the durvalumab combination cohort, seven of the 17 patients (41.2%) achieved a PR, and gene expression analysis revealed that durvalumab responders exhibited high immune/stromal cell infiltration, mainly comprising natural killer cells, compared to non-responders as well as increased expression of CD19, a B-cell marker. Conclusion Despite the limitation of heterogeneity in the study population and treatment, we identified possible molecular predictors of pazopanib efficacy that can be employed in future clinical trials aimed at evaluating therapeutic strategies. | Hong, Jung Yong; Cho, Hee Jin; Yun, Kum-Hee; Lee, Young Han; Kim, Seung Hyun; Baek, Wooyeol; Kim, Sang Kyum; Lee, Yurimi; Choi, Yoon-La; Kwon, Minsuk; Kim, Hyo Song; Lee, Jeeyun | Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; Kyungpook Natl Univ, Dept Biomed Convergence Sci & Technol, Daegu, South Korea; Kyungpook Natl Univ, Cell & Matrix Res Inst, Daegu, South Korea; Yonsei Univ, Dept Internal Med, Div Med Oncol, Coll Med, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Radiol, Seoul, South Korea; Yonsei Univ, Dept Orthoped Surg, Coll Med, Seoul, South Korea; Yonsei Univ, Severance Hosp, Inst Human Tissue Restorat, Dept Plast & Reconstruct Surg,Coll Med, Seoul, South Korea; Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, Seoul, South Korea; Ajou Univ, Dept Hematol Oncol, Sch Med, Suwon, South Korea; Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, 50 Yonsei Ro, Seoul 03722, South Korea | Lee, Yo Han/IUN-3410-2023; Kim, Hyun/D-5568-2011; KIM, JIN/I-6927-2019 | 57212848586; 55937716400; 57219005117; 57225667591; 57284252700; 56990792600; 55877447800; 57490012500; 7404777529; 57191612194; 57226091353; 55899617000 | hyosong77@yuhs.ac; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 2 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 0.45 | 2025-06-25 | 3 | 3 | Soft tissue sarcoma; Pazopanib; Immune checkpoint inhibitors; Whole exome sequencings; Whole transcriptome sequencing | PHASE-II; SURVIVAL; EORTC | Immune checkpoint inhibitors; Pazopanib; Soft tissue sarcoma; Whole exome sequencings; Whole transcriptome sequencing | Humans; Indazoles; Pyrimidines; Sarcoma; Sulfonamides; cyclin dependent kinase 4; docetaxel; doxorubicin; durvalumab; eribulin; gemcitabine; ifosfamide; olaratumab; pazopanib; programmed death 1 ligand 1; vasculotropin; indazole derivative; pazopanib; pyrimidine derivative; sulfonamide; adult; aged; Article; blood sampling; cancer chemotherapy; clear cell sarcoma; clinical article; clinical feature; cohort analysis; dedifferentiated liposarcoma; desmoplastic small round cell tumor; differential expression analysis; down regulation; drug efficacy; false discovery rate; female; gene amplification; gene dosage; gene expression level; gene expression profiling; gene set enrichment analysis; genomic instability; histopathology; human; human tissue; immune response; leiomyosarcoma; male; malignant peripheral nerve sheath tumor; metastasis; mismatch repair; molecular fingerprinting; monotherapy; patient history of chemotherapy; primary tumor; progression free survival; protein expression; soft tissue sarcoma; telomere; transcriptome sequencing; treatment response; tumor microenvironment; tumor mutational burden; upregulation; whole transcriptome sequencing; genetics; sarcoma | English | 2023 | 2023-04 | 10.4143/crt.2022.251 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study | Purpose A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma.Materials and Methods In this phase II study, we enrolled 45 patients who achieved a very good partial response (VGPR) or partial response (PR) after autologous stem cell transplantation (ASCT) and evaluated the efficacy and toxicity of CVD consolidation. CVD consolidation comprised three cycles of cyclophosphamide 300 mg/m2 orally on days 1, 8, and 15, and bortezomib 1.3 mg/m2 sub-cutaneously on days 1, 8, 15, and 22, along with dexamethasone 20 mg orally or intravenously on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23.Results At enrollment, 39 patients (86.7%) showed VGPR, and nine (13.3%) presented with PR. Nineteen patients (45.2%) achieved a complete response or better as their best response after the end of consolidation. Overall, 22 of 42 patients (52.4%) experienced an improved response status with CVD consolidation. Three-year overall survival and progression-free survival rates were 89.0% and 42.7%, respectively. The most common non-hematologic toxicities were peripheral neuropathy and infection (20.5%), with no grade =3 neuropathy observed.Conclusion These results showed that CVD consolidation therapy improved the response with reasonable toxicity in patients with residual disease after ASCT. This trial was registered with the Clinical Research Information Service, Republic of Korea (KCT0001327). | Jung, Jongheon; Kim, Kihyun; Jung, Sung-Hoon; Yoon, Sung -Soo; Lee, Jae Hoon; Kim, Jin Seok; Shin, Ho-Jin; Bang, Soo -Mee; Sohn, Sang Kyun; Suh, Cheolwon; Yoon, Dok Hyun; Kong, Sun -Young; Min, Chang-Ki; Eom, Hyeon-Seok | Natl Canc Ctr, Ctr Hematol Malignancies, Goyang, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Gachon Univ, Dept Internal Med, Div Hematol, Gil Med Ctr, Incheon, South Korea; Yonsei Univ, Severance Hosp, Dept Internal Med, Div Hematol,Coll Med, Seoul, South Korea; Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Hematol Oncol, Sch Med, Busan, South Korea; Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea; Natl Canc Ctr, Res Inst, Targeted Therapy Branch, Goyang, South Korea; Natl Canc Ctr, Dept Lab Med, Goyang, South Korea; Natl Canc Ctr, Dept Canc Biomed Sci, Grad Sch Canc Sci & Policy, Goyang, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Hematol, Seoul, South Korea; Natl Canc Ctr, Ctr Hematol Malignancies, 323 Ilsan Ro, Goyang 10408, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Dept Hematol, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea | Kim, Kihyun/D-5175-2013; KIM, JIN/I-6927-2019; Kong, Sun-Young/ABB-7914-2021; Liu, Jingwei/AAZ-9739-2021 | 57195917971; 57199440300; 55511978300; 7404036304; 56013463700; 55032033600; 16239868400; 7102038069; 13310226800; 7102970953; 57225086458; 12804432400; 57224962914; 35268272400 | ckmin@catholic.ac.kr;hseom@ncc.re.kr; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 2 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 0.45 | 2025-06-25 | 3 | 3 | Multiple myeloma; Consolidation; Bortezomib; Cyclophosphamide; Dexamethasone | LENALIDOMIDE MAINTENANCE; RANDOMIZED-TRIAL; PHASE-II; THALIDOMIDE; THERAPY; INDUCTION; MARKERS | Bortezomib; Consolidation; Cyclophosphamide; Dexamethasone; Multiple myeloma | bortezomib; cyclophosphamide; dexamethasone; adult; Article; autologous stem cell transplantation; combination drug therapy; demographics; drug efficacy; female; human; infection; major clinical study; male; multicenter study; multiple myeloma; open study; overall survival; peripheral neuropathy; phase 2 clinical trial; progression free survival; treatment response | English | 2023 | 2023-04 | 10.4143/crt.2022.952 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor | Background: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measurement.Objectives: We conducted this study to identify the prognostic factors for successful treatment-free remission in patients with chronic-phase chronic myeloid leukemia who discontinued tyrosine kinase inhibitors (TKIs). We also aimed to validate ddPCR for predicting molecular relapse.Design: This is a prospective, multicenter study.Methods: We enrolled patients treated with TKIs for at least 3 years with a confirmed sustained deep molecular response (DMR) for at least 1 year. TKI was re-administered in patients who experienced the loss of major molecular response (MMR).Results: A total of 66 patients from five institutions in South Korea were enrolled. During a median follow-up period of 16.5 months, 29/66 (43.9%) patients experienced molecular relapse; the probability of molecular relapse-free survival (RFS) at 6 or 12 months after TKI discontinuation was 65.6% or 57.8%, respectively, with most molecular relapses occurring within the first 7 months. All patients who lost MMR were re-treated with TKI, and all re-achieved MMR at a median of 2.8 months. E14a2 transcript type (p = 0.005) and longer DMR duration (>= 48 months) prior to TKI discontinuation (p = 0.002) were associated with prolonged molecular RFS and with sustained DMR. Patients with both e13a2 transcript type and detectable BCR::ABL1 (>= MR5.0) by ddPCR at the time of TKI discontinuation showed shorter duration of molecular RFS (p = 0.015).Conclusion: Our data suggest that transcript type and BCR::ABL1 transcript levels on ddPCR should be taken into consideration when deciding whether to discontinue TKI therapy. | Park, Hyunkyung; Kim, Hyeong-Joon; Sohn, Sang-Kyun; Baik, Yoonsuk; Kim, Dongho; Lee, Sung-Yeoun; Kong, Jee Hyun; Kim, Hawk; Shin, Dong-Yeop; Ahn, Jae-Sook; Park, Jinny; Park, Seonyang; Kim, Inho | Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, 101 Daehak Ro, Seoul 03080, South Korea; Seoul Natl Univ, Seoul Metropolitan Govt Boramae Med Ctr, Dept Internal Med, Seoul, South Korea; Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Hwasun, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; LAS Inc, Gimpo, South Korea; Yonsei Univ Wonju Coll Med, Wonju Severance Christian Hosp, Dept Internal Med, Wonju, South Korea; Gachon Univ Gil Med Ctr, Dept Internal Med, Incheon, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea; Inje Univ, Haeundae Paik Hosp, Dept Internal Med, Busan, South Korea | Lee, Sungyeoun/ACR-8079-2022; Park, Jun Won/KSM-8932-2024; Park, Jinwoo/AAD-1328-2022 | 57203771773; 7410127473; 13310226800; 58693722600; 58688945000; 57295837100; 56225377900; 57218435122; 36492559200; 22984055900; 35277336100; 57049842400; 55712969800 | ihkimmd@snu.ac.kr; | THERAPEUTIC ADVANCES IN HEMATOLOGY | THER ADV HEMATOL | 2040-6207 | 2040-6215 | 14 | SCIE | HEMATOLOGY | 2023 | 3.4 | 28.4 | 0.44 | 2025-06-25 | 2 | 3 | chronic myeloid leukemia; droplet digital polymerase chain reaction; transcript type; treatment-free remission; tyrosine kinase inhibitor | CML PATIENTS; MOLECULAR RESPONSE; IMATINIB; RELAPSE; LONGER; E13A2 | chronic myeloid leukemia; droplet digital polymerase chain reaction; transcript type; treatment-free remission; tyrosine kinase inhibitor | BCR ABL protein; dasatinib; imatinib; nilotinib; protein tyrosine kinase inhibitor; radotinib; adult; agar gel electrophoresis; aged; Article; chronic myeloid leukemia; disease exacerbation; droplet digital polymerase chain reaction; female; human; major clinical study; male; multicenter study; polymerase chain reaction; prospective study; real time reverse transcription polymerase chain reaction; recurrence free survival; remission; reverse transcription polymerase chain reaction | English | 2023 | 2023 | 10.1177/20406207231205637 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data | Purpose Renal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic nephroma (CMN) and other rare tumors. We investigated the epidemiology of pediatric renal tumors in Korea. Materials and Methods From January 2001 to December 2015, data of pediatric patients (0-18 years) newly-diagnosed with renal tumors at 26 hospitals were retrospectively analyzed.Results Among 439 patients (male, 240), the most common tumor was WT (n=342, 77.9%), followed by RCC (n=36, 8.2%), CCSK (n=24, 5.5%), MRTK (n=16, 3.6%), CMN (n=12, 2.7%), and others (n=9, 2.1%). Median age at diagnosis was 27.1 months (range, 0 to 225.5 months) and median follow-up duration was 88.5 months (range, 0 to 211.6 months). Overall, 32 patients died, of whom 17, 11, 1, and three died of relapse, progressive disease, second malignant neoplasm, and treatment-related mortality. Five-year overall survival and event-free survival were 97.2% and 84.8% in WT, 90.6% and 82.1% in RCC, 81.1% and 63.6% in CCSK, 60.3% and 56.2% in MRTK, and 100% and 91.7% in CMN, respectively (p < 0.001).Conclusion The pediatric renal tumor types in Korea are similar to those previously reported in other countries. WT accounted for a large proportion and survival was excellent. Non-Wilms renal tumors included a variety of tumors and showed inferior outcome, especially MRTK. Further efforts are necessary to optimize the treatment and analyze the genetic characteristics of pediatric renal tumors in Korea. | Koh, Kyung-Nam; Han, Jung Woo; Choi, Hyoung Soo; Kang, Hyoung Jin; Lee, Ji Won; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong Hoe; Hong, Kyung Taek; Choi, Jung Yoon; Kang, Sung Han; Kim, Hyery; Im, Ho Joon; Hahn, Seung Min; Lyu, Chuhl Joo; Baek, Hee-Jo; Kook, Hoon; Park, Kyung Mi; Yang, Eu Jeen; Lim, Young Tak; Kim, Seongkoo; Lee, Jae Wook; Chung, Nack-Gyun; Cho, Bin; Park, Meerim; Park, Hyeon Jin; Park, Byung-Kiu; Lee, Jun Ah; Park, Jun Eun; Kim, Soon Ki; Kim, Ji Yoon; Kim, Hyo Sun; Ma, Youngeun; Park, Kyung Duk; Park, Sang Kyu; Park, Eun Sil; Shim, Ye Jee; Yoo, Eun Sun; Ha Ryu, Kyung; Yoo, Jae Wo; Lim, Yeon Jung; Yoon, Hoi Soo; Lee, Mee Jeong; Lee, Jae Min; Jeon, In-Sang; Jung, Hye Lim; Chueh, Hee Won; Won, Seunghyun | Univ Ulsan, Asan Med Ctr Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol,Coll Med, Seoul, South Korea; Yonsei Univ, Coll Med, Div Pediat Hematol & Oncol, Dept Pediat, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Pediat, Coll Med, Seongnam, South Korea; Seoul Natl Univ, Dept Pediat, Coll Med, Seoul, South Korea; Seoul Natl Univ, Canc Inst, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Pediat, Sch Med, Seoul, South Korea; Chonnam Natl Univ, Hwasun Hosp, Dept Pediat, Med Sch, Gwangju, South Korea; Pusan Natl Univ, Dept Pediat, Sch Med, Yangsan, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Pediat, Seoul, South Korea; Natl Canc Ctr, Ctr Pediat Canc, Dept Pediat, Goyang, South Korea; Korea Canc Ctr Hosp, Dept Pediat, Seoul, South Korea; Korea Univ, Dept Pediat, Sch Med, Seoul, South Korea; Inha Univ, Inha Univ Hosp, Dept Pediat, Coll Med, Incheon, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Pediat, Daegu, South Korea; Inje Univ, Haeundae Paik Hosp, Dept Pediat, Pusan, South Korea; Jeonbuk Natl Univ, Dept Pediat, Med Sch, Jeonbuk Natl Univ Hosp, Jeonju, South Korea; Jeonbuk Natl Univ, Res Inst Clin Med, Jeonbuk Natl Univ Hosp, Med Sch, Jeonju, South Korea; Univ Ulsan, Ulsan Univ Hosp, Dept Pediat, Coll Med, Ulsan, South Korea; Gyeongsang Natl Univ, Dept Pediat, Sch Med, Jinju, South Korea; Keimyung Univ, Sch Med, Dept Pediat, Dongsan Hosp, Daegu, South Korea; Ewha Womans Univ, Coll Med, Dept Pediat, Seoul Hosp, Seoul, South Korea; Chungnam Natl Univ, Dept Pediat, Coll Med, Daejeon, South Korea; Kyung Hee Univ, Dept Pediat, Coll Med, Seoul, South Korea; Dankook Univ, Dept Pediat, Coll Med, Cheonan, South Korea; Yeungnam Univ, Dept Pediat, Coll Med, Daegu, South Korea; Gachon Univ, Dept Pediat, Gil Med Ctr, Incheon, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Pediat, Sch Med, Seoul, South Korea; Dong A Univ, Dept Pediat, Coll Med, Pusan, South Korea; Seoul Natl Univ, Med Res Collaborating Ctr, Bundang Hosp, Seongnam, South Korea; Dongnam Inst Radiol & Med Sci, Dept Pediat, Busan, South Korea; Korea Univ, Dept Pediat, Med Ctr, Seoul, South Korea | Choi, Jungyoon/AAA-3883-2021; Koh, Kyung-Nam/AAA-2747-2022; Kim, Jung Oh/JDC-5061-2023; Hahn, Seung min/MBH-8374-2025; kim, jeeyoung/AFK-5620-2022; Han, Jung Woo/ABI-6899-2022; Lee, Jae Wook/KFS-2583-2024; Lee, Jae Min/H-8475-2013; Chung, Chun/J-5650-2012; Kim, Sang-Hyun/J-5402-2012; Park, Jun/AAL-8733-2020 | 36508814500; 56927055400; 24576435400; 7404071502; 57217265353; 35304229600; 34873631300; 7102120540; 55145561500; 57102078500; 55496441700; 57196215369; 14524798500; 57964813500; 7004643628; 36724802200; 7006255531; 57196342718; 56594276100; 7402565128; 58172875400; 59448673500; 24074375300; 58173730600; 36626096800; 35739156500; 35300225600; 23097522100; 35488820600; 55190025100; 57205408095; 59051212900; 57190860767; 7408065158; 57209835309; 26030635800; 57222517942; 20936704200; 14038236200; 58305386300; 23972945200; 24328910900; 56080197500; 39261799700; 34975052900; 7403029925; 39261421100; 57237459900; 58173300000; 59276790400; 58755758900; 54782638200; 59828953600; 56396023400; 57757690300; 57714619600; 58205809000; 58173945400; 59624006200; 57191927280; 57981670900; 56645629700; 58705340400; 58334596700; 57909190400; 57206876373; 57218595050; 59716173200; 57789898000; 9939502400; 54405040100; 37043844700; 58705381600; 58363796100; 55486370800; 59088181100; 56468388800; 58705340900; 58705426500; 58839314600; 59580602700; 55906474200; 7006609239; 59436280400; 57193060539; 58067520000; 58332935900; 58456731900; 58705327100; 59863544400; 59089681700; 57191896853 | choihs1786@snubh.org;kanghj@snu.ac.kr; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 1 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 0.61 | 2025-06-25 | 4 | 4 | Kidney neoplasms; Child; Epidemiology | WILMS-TUMOR; KIDNEY; PROTOCOLS; TURNOURS; BIOLOGY | Child; Epidemiology; Kidney neoplasms | Carcinoma, Renal Cell; Child; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Nephroma, Mesoblastic; Republic of Korea; Retrospective Studies; Rhabdoid Tumor; Sarcoma; Wilms Tumor; adolescent; adult; Article; cancer patient; cancer recurrence; cancer survival; child; childhood cancer; clinical outcome; congenital mesoblastic nephroma; event free survival; female; follow up; genetic trait; human; infant; kidney sarcoma; kidney tumor; major clinical study; male; mortality; nephroblastoma; newborn; overall survival; pediatric patient; renal cell carcinoma; rhabdoid tumor; second cancer; South Korea; kidney tumor; mesoblastic nephroma; metabolism; nephroblastoma; pathology; renal cell carcinoma; retrospective study; rhabdoid tumor; sarcoma; South Korea; tumor recurrence | English | 2023 | 2023-01 | 10.4143/crt.2022.073 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: